Gilead Sciences, Inc. (GILD)
$
118.5
+0.62 (0.52%)
Key metrics
Financial statements
Free cash flow per share
7.5253
Market cap
149.8 Billion
Price to sales ratio
5.1907
Debt to equity
1.2679
Current ratio
1.3154
Income quality
1.5636
Average inventory
1.8 Billion
ROE
0.3294
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines addressing unmet medical needs in the United States, Europe, and internationally. The company has achieved a significant net income of $480,000,000.00 showcasing its strong financial health. The diluted EPS is $0.38 accounting for potential share dilution, which is an important metric for investors. Furthermore, the net income ratio stands at 0.02 reflecting the company's profitability margin effectively. Gilead's EBITDA is $4,434,000,000.00 serving as a key indicator of its operational profitability. Additionally, the gross profit ratio of 0.78 reflects the efficiency of the company's production and sales operations. The product portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla for HIV/AIDS treatment, as well as Veklury for COVID-19. Gilead also offers therapies for liver diseases, hematology, oncology, and related cell therapies. The company's collaborations with notable partners such as Arcus Biosciences, Pionyr Immunotherapeutics, and Bristol-Myers Squibb exemplify its strategic approach to innovation. Incorporated in 1987, Gilead is headquartered in Foster City, California. The stock is reasonably priced at $114.09 appealing to a broad range of investors. With a large market capitalization of $147,035,619,546.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its category. Moreover, the stock has a high average trading volume of 6,919,198.00 indicating strong liquidity, which is an essential factor for investors seeking reliable investments. By fulfilling unmet medical needs and maintaining strong financial metrics, Gilead Sciences continues to be a vital entity in its field, dedicated to providing effective solutions for serious health conditions while upholding a commitment to improvement and advancement in biopharmaceutical science.
Is Gilead Sciences, Inc. (GILD) a good investment?
Investing in Gilead Sciences, Inc. (GILD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Gilead Sciences, Inc. (GILD)'s stock forecast?
Analysts predict Gilead Sciences, Inc. stock to fluctuate between $86.08 (low) and $124.61 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Gilead Sciences, Inc.'s market capitalization?
As of 2025-10-29, Gilead Sciences, Inc.'s market cap is $147,035,619,546, based on 1,240,806,916 outstanding shares.
How does Gilead Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Gilead Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Gilead Sciences, Inc. pay dividends?
Gilead Sciences, Inc. pays dividends. The current dividend yield is 2.79%, with a payout of $0.79 per share.
How can I buy Gilead Sciences, Inc. (GILD) stock?
To buy Gilead Sciences, Inc. (GILD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GILD. Place an order (Market, Limit, etc.).
What is the best time to invest in Gilead Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Gilead Sciences, Inc. stock ever split?
Gilead Sciences, Inc.'s last stock split was 2:1 on 2013-01-28.
How did Gilead Sciences, Inc. perform in the last earnings report?
Revenue: $28,754,000,000 | EPS: $0.38 | Growth: -91.63%.
Where can I find Gilead Sciences, Inc.'s investor relations reports?
Visit https://www.gilead.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Gilead Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Gilead Sciences, Inc. stock?
All-time high: $124.61 (2025-10-21) | All-time low: $57.17 (2022-06-14).
What are the key trends affecting Gilead Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communit.
reuters.com
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented to.
seekingalpha.com
Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism, with FDA approval and delayed Biktarvy exclusivity boosting long-term prospects. Valuation remains attractive, with technical analysis signaling potential upside to $150 in the near term and $185 longer term.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initiatives, key collaborations, and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2025, along with the Gilead-led symposia and supported.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21. Potentially Practice-Changing Results for First-Line Metastatic TNBC Treatment A late-breaking presentation (#LBA20) will feature full results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy) as.
zacks.com
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an additional 100% tariff on Chinese goods starting November 1st.
zacks.com
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zacks.com
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
See all news
